<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK5942" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK5942/" /><meta name="ncbi_pagename" content="TARDBP-Related Amyotrophic Lateral Sclerosis - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>TARDBP-Related Amyotrophic Lateral Sclerosis - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="TARDBP-Related Amyotrophic Lateral Sclerosis" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/03/12" /><meta name="citation_author" content="Matthew M Harms" /><meta name="citation_author" content="Timothy M Miller" /><meta name="citation_author" content="Robert H Baloh" /><meta name="citation_pmid" content="20301761" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK5942/" /><meta name="citation_keywords" content="TARDBP-Related ALS" /><meta name="citation_keywords" content="TAR DNA-binding protein 43" /><meta name="citation_keywords" content="TARDBP" /><meta name="citation_keywords" content="TARDBP-Related Amyotrophic Lateral Sclerosis" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="TARDBP-Related Amyotrophic Lateral Sclerosis" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Matthew M Harms" /><meta name="DC.Contributor" content="Timothy M Miller" /><meta name="DC.Contributor" content="Robert H Baloh" /><meta name="DC.Date" content="2015/03/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK5942/" /><meta name="description" content="TARDBP-related amyotrophic lateral sclerosis (TARDBP-related ALS) is characterized by upper motor neuron (UMN) and lower motor neuron (LMN) disease that appears indistinguishable from ALS of other known and unknown causes based on gender ratio, age of onset, symptom distribution, and severity of disease. The male to female ratio is 1.6 to 1. Mean age of onset is 54 ± 12 years. UMN manifestations can include stiffness, spasticity, hyperreflexia, and pseudobulbar affect; LMN manifestations often include weakness accompanied by muscle atrophy, fasciculations, and cramping. Limb onset occurs in 80% and bulbar onset in 20%. Affected individuals typically succumb to respiratory failure when phrenic and thoracic motor neurons become severely involved." /><meta name="og:title" content="TARDBP-Related Amyotrophic Lateral Sclerosis" /><meta name="og:type" content="book" /><meta name="og:description" content="TARDBP-related amyotrophic lateral sclerosis (TARDBP-related ALS) is characterized by upper motor neuron (UMN) and lower motor neuron (LMN) disease that appears indistinguishable from ALS of other known and unknown causes based on gender ratio, age of onset, symptom distribution, and severity of disease. The male to female ratio is 1.6 to 1. Mean age of onset is 54 ± 12 years. UMN manifestations can include stiffness, spasticity, hyperreflexia, and pseudobulbar affect; LMN manifestations often include weakness accompanied by muscle atrophy, fasciculations, and cramping. Limb onset occurs in 80% and bulbar onset in 20%. Affected individuals typically succumb to respiratory failure when phrenic and thoracic motor neurons become severely involved." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK5942/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/tardbp-als/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK5942/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8BF993DFC8FD4100000000001F000D.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK5942_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK5942_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/tango2-mea/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/tbc1d24-dis/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK5942_"><span class="title" itemprop="name"><i>TARDBP</i>-Related Amyotrophic Lateral Sclerosis</span></h1><p class="contrib-group"><span itemprop="author">Matthew M Harms</span>, MD, <span itemprop="author">Timothy M Miller</span>, MD, PhD, and <span itemprop="author">Robert H Baloh</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK5942_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK5942_ai__"><div class="contrib half_rhythm"><span itemprop="author">Matthew M Harms</span>, MD<div class="affiliation small">Department of Neurology<br />Neuromuscular Division<br />Washington University School of Medicine<br />St Louis, Missouri<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.ltsuw.oruen@msmrah" class="oemail">ude.ltsuw.oruen@msmrah</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Timothy M Miller</span>, MD, PhD<div class="affiliation small">Department of Neurology<br />Neuromuscular Division<br />Washington University School of Medicine<br />St Louis, Missouri<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.ltsuw.oruen@trellim" class="oemail">ude.ltsuw.oruen@trellim</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Robert H Baloh</span>, MD, PhD<div class="affiliation small">Department of Neurology<br />Cedars Sinai Medical Center<br />Los Angeles, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmsc@holab.trebor" class="oemail">ude.cmsc@holab.trebor</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">April 23, 2009</span>; Last Update: <span itemprop="dateModified">March 12, 2015</span>.</p><p><em>Estimated reading time: 23 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="tardbp-als.Summary" itemprop="description"><h2 id="_tardbp-als_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>TARDBP</i>-related amyotrophic lateral sclerosis (<i>TARDBP</i>-related ALS) is characterized by upper motor neuron (UMN) and lower motor neuron (LMN) disease that appears indistinguishable from ALS of other known and unknown causes based on gender ratio, age of onset, symptom distribution, and severity of disease. The male to female ratio is 1.6 to 1. Mean age of onset is 54 &#x000b1; 12 years. UMN manifestations can include stiffness, spasticity, hyperreflexia, and pseudobulbar affect; LMN manifestations often include weakness accompanied by muscle atrophy, fasciculations, and cramping. Limb onset occurs in 80% and bulbar onset in 20%. Affected individuals typically succumb to respiratory failure when phrenic and thoracic motor neurons become severely involved.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of ALS is established by clinical examination, neurophysiologic testing, and neuroimaging. <i>TARDBP</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> associated with <i>TARDBP</i>-related ALS.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Spasticity can be treated with a spasmolytic such as baclofen or a benzodiazepine; pseudobulbar affect can be treated with a tricyclic antidepressant or combination of quinidine and dextromethorphan; sialorrhea is often managed with anticholinergic medications (tricyclic antidepressants, scopolamine, atropine drops) or botulinum toxin injection of the salivary glands; antidepressants are often required to treat concurrent depression; it is reasonable to consider use of riluzole, the only FDA-approved treatment for any type of ALS.</p><p><i>Prevention of secondary complications:</i> Percutaneous gastrostomy can be used to maintain adequate caloric intake in persons with significant bulbar involvement; appropriate bracing and stretching can minimize contractures; noninvasive ventilation can be initiated when appropriate.</p><p><i>Surveillance:</i> At clinic visits: monitoring of ventilatory function and screening for depression.</p><p><i>Agents/circumstances to avoid:</i> Long-term use of minocycline; excessive exercise to the point of inducing fatigue.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>TARDBP</i>-related ALS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. The proportion of cases caused by <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants is unknown. Each child of an individual with <i>TARDBP</i>-related ALS has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Prenatal diagnosis for <i>TARDBP</i>-related ALS is possible if the pathogenic variant has been identified in the family.</p></div></div><div id="tardbp-als.Diagnosis"><h2 id="_tardbp-als_Diagnosis_">Diagnosis</h2><p>A diagnosis of <i>TARDBP</i>-related amyotrophic lateral sclerosis (<i>TARDBP</i>-related ALS) is established when a <i>TARDBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified in an individual meeting clinical diagnostic criteria for ALS (i.e., characteristic signs and symptoms of progressive degeneration of upper motor neurons (UMNs) and lower motor neurons [LMNs]).</p><ul><li class="half_rhythm"><div>UMN manifestations include stiffness, spasticity, hyperreflexia, and pseudobulbar affect</div></li><li class="half_rhythm"><div>LMN manifestations include weakness accompanied by muscle atrophy, fasciculations, and cramping</div></li></ul><p>(See the El Escorial criteria [<a class="bk_pop" href="#tardbp-als.REF.brooks.2000.293">Brooks et al 2000</a>].)</p><p>Note: <i>TARDBP-</i>related ALS is clinically indistinguishable from ALS due to other causes.</p><p>See <a href="/books/n/gene/als-overview/">Amyotrophic Lateral Sclerosis Overview</a> for a more detailed description of these features.</p><div id="tardbp-als.Testing"><h3>Testing</h3><p>Clinical testing in <i>TARDBP</i>-related ALS is identical to that for other forms of ALS, employing multiple modalities to exclude alternative diagnoses and to provide support for the diagnosis of ALS. Following a diagnosis of ALS, genetic testing for <i>TARDBP</i> pathogenic variants can be considered (see <a href="#tardbp-als.Testing_Strategy">Testing Strategy</a>).</p><p><b>Electromyography and nerve conduction studies (EMG/NCS).</b> EMG/NCS are often used to support a diagnosis of ALS and to exclude mimics of ALS (e.g., polyradiculopathy, mononeuritis multiplex, multifocal motor neuropathy, sensory motor neuropathies). EMG/NCS in <i>TARDBP-</i>related ALS, as in other causes of ALS, demonstrates widespread denervation due to LMN loss in the setting of relatively preserved sensory responses [<a class="bk_pop" href="#tardbp-als.REF.gitcho.2008.535">Gitcho et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.k_hnlein.2008.1185">K&#x000fc;hnlein et al 2008</a>].</p><p><b>Neuroimaging.</b> MRI of the brain and spinal cord are used in the evaluation to exclude alternate explanations for the observed symptoms, including polyradiculopathy and spinal cord or brain lesions. Although several imaging abnormalities have been directly attributed to ALS, including abnormal T<sub>2</sub> signal along the corticospinal tracts and atrophy of the precentral gyrus, the poor <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> and specificity of these findings limit their usefulness in confirming the diagnosis of ALS [<a class="bk_pop" href="#tardbp-als.REF.grosskreutz.2008.238">Grosskreutz et al 2008</a>]. If frontotemporal dementia is also present, atrophy of the frontal and temporal lobes may be present [<a class="bk_pop" href="#tardbp-als.REF.floris.2015.375">Floris et al 2015</a>]. Although the imaging characteristics of <i>TARDBP</i>-related ALS have not been systematically investigated, single cases have had unremarkable MRI of the brain and cervical spinal cord [<a class="bk_pop" href="#tardbp-als.REF.k_hnlein.2008.1185">K&#x000fc;hnlein et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.pamphlett.2009.222">Pamphlett et al 2009</a>].</p><p><b>Cerebrospinal fluid (CSF).</b> Analysis of the CSF is primarily used to exclude conditions with overlapping features of ALS, including infectious polyradiculitis and carcinomatosis or lymphomatosis. TAR DNA-binding protein 43 (TDP-43), the protein encoded by <i>TARDBP</i>, has been detected in the CSF of individuals with ALS of unknown cause [<a class="bk_pop" href="#tardbp-als.REF.steinacker.2008.1481">Steinacker et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.kasai.2009.55">Kasai et al 2009</a>]. It has only been examined in a single individual with <i>TARDBP-</i>related ALS, and this individual had substantially higher levels than individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> ALS [<a class="bk_pop" href="#tardbp-als.REF.nozaki.2010.1209">Nozaki et al 2010</a>].</p><p><b>Neuropathology.</b> Pathologic evaluation of the brain and spinal cord can be utilized to confirm a diagnosis of ALS post mortem. One of the pathologic hallmarks of ALS is the presence of ubiquitin-immunoreactive cytoplasmic inclusions in degenerating cortical and spinal cord neurons. In non-<i>SOD1</i> ALS (including <i>TARBP</i>-associated ALS), these cytoplasmic inclusions typically contain TDP-43, which is also reduced or absent from the nuclei of inclusion-containing cells [<a class="bk_pop" href="#tardbp-als.REF.neumann.2006.130">Neumann et al 2006</a>, <a class="bk_pop" href="#tardbp-als.REF.davidson.2007.521">Davidson et al 2007</a>]. However, TDP-43-positive inclusions are not specific for ALS and have also been described in other neurodegenerative diseases [<a class="bk_pop" href="#tardbp-als.REF.freeman.2008.62">Freeman et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.uryu.2008.555">Uryu et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.arai.2009.125">Arai et al 2009</a>] and in several diseases of muscle [<a class="bk_pop" href="#tardbp-als.REF.weihl.2008.1186">Weihl et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.k_sters.2009.209">K&#x000fc;sters et al 2009</a>, <a class="bk_pop" href="#tardbp-als.REF.oliv_.2009.262">Oliv&#x000e9; et al 2009</a>].</p></div><div id="tardbp-als.Molecular_Genetic_Testing"><h3>Molecular Genetic Testing</h3><p><b>Gene.</b>
<i>TARDBP</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause <i>TARDBP</i>-related ALS.</p><div id="tardbp-als.T.molecular_genetic_testing_u" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>TARDBP</i>-Related Amyotrophic Lateral Sclerosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5942/table/tardbp-als.T.molecular_genetic_testing_u/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tardbp-als.T.molecular_genetic_testing_u_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tardbp-als.T.molecular_genetic_testing_u_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_tardbp-als.T.molecular_genetic_testing_u_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_tardbp-als.T.molecular_genetic_testing_u_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_tardbp-als.T.molecular_genetic_testing_u_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TARDBP</i></td><td headers="hd_h_tardbp-als.T.molecular_genetic_testing_u_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>2</sup></td><td headers="hd_h_tardbp-als.T.molecular_genetic_testing_u_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Approaches 100%&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_tardbp-als.T.molecular_genetic_testing_u_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_tardbp-als.T.molecular_genetic_testing_u_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 5</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="tardbp-als.TF.1.1"><p class="no_margin">See <a href="/books/NBK5942/#tardbp-als.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#tardbp-als.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>2. </dt><dd><div id="tardbp-als.TF.1.2"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>3. </dt><dd><div id="tardbp-als.TF.1.3"><p class="no_margin">Because <i>TARDBP</i>-related ALS is defined by the presence of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TARDBP</i>, and because variant types that are not detected by <a href="/books/n/gene/glossary/def-item/sequence-analysis/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">sequence analysis</a> (e.g., <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a href="/books/n/gene/glossary/def-item/gene/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">gene</a> deletions) have not been reported, the variant detection rate for <i>TARDBP</i> using sequence analysis approaches 100%.</p></div></dd><dt>4. </dt><dd><div id="tardbp-als.TF.1.4"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>5. </dt><dd><div id="tardbp-als.TF.1.5"><p class="no_margin">No large deletions or insertions have been reported. Screening for these types of variants has been reported in 714 patients using rt-<a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> or multiplexed amplicon quantification (MAQ) [<a class="bk_pop" href="#tardbp-als.REF.guerreiro.2008.e2450">Guerreiro et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.rutherford.2008.e1000193">Rutherford et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.b_umer.2009.1283">B&#x000e4;umer et al 2009</a>, <a class="bk_pop" href="#tardbp-als.REF.benajiba.2009.470">Benajiba et al 2009</a>, <a class="bk_pop" href="#tardbp-als.REF.gijselinck.2009.1329">Gijselinck et al 2009</a>]. Since the proposed mechanism that leads to <i>TARDBP</i>-related ALS is <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> of TARDBP, it is unlikely that copy number variants in <i>TARDBP</i> will comprise a significant number of cases.</p></div></dd></dl></div></div></div></div><div id="tardbp-als.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To establish the diagnosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">Establish a clinical diagnosis of ALS using clinical examination, neurophysiologic testing, and neuroimaging. Note: <i>TARDBP-</i>related ALS is clinically indistinguishable from ALS resulting from other causes.</div></li><li class="half_rhythm"><div class="half_rhythm">Obtain a three-generation family history. The presence of ALS in a closely related family member (usually a parent) increases the probability that a <i>TARDBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may be found. If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is the only occurrence of ALS in their family, i.e. a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case, the likelihood of identifying a <i>TARDBP</i> pathogenic variant is lower.</div><div class="half_rhythm">Note: (1) To date, all reported pedigrees with <i>TARDBP</i>-related ALS show <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance; (2) Several genetic causes of ALS are more common than <i>TARDBP</i>-related ALS (see below).</div></li></ul><p><b>Familial ALS (FALS) (i.e., presence of at least two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members)</b></p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> One genetic testing strategy is serial single-gene <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> based on the order in which pathogenic variants most commonly occur.</p><ul><li class="half_rhythm"><div>In most white populations, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in the following order is recommended:</div><ul><li class="half_rhythm"><div>Testing for an expansion of the hexanucleotide repeat in <i>C9ORF72</i> (accounting for ~40%-50% of FALS) should be done first.</div></li><li class="half_rhythm"><div>If no expansion is identified in <i>C9ORF72</i>, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>SOD1</i> (accounting for ~20% of FALS) should be considered next.</div></li><li class="half_rhythm"><div>If <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>C9ORF72</i> and <i>SOD1</i> does not reveal a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, molecular genetic testing of <i>TARDBP</i> and/or <i>FUS</i> (together accounting for &#x0003c;5% of cases) should be considered next<i>.</i></div></li></ul></li><li class="half_rhythm"><div>In individuals of Asian or African background, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>SOD1</i> should be considered first<i>.</i></div></li><li class="half_rhythm"><div>In Sardinia, where <i>C9ORF72</i> expansions and <i>TARDBP</i> pathogenic variants account for most cases and at times coexist in the same family, simultaneous <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of both genes could be considered.</div></li></ul><p><b>Multigene panel.</b> An alternative genetic testing strategy is use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>C9ORF72, SOD1</i>, <i>TARDBP</i>, and other genes of interest (see <a href="#tardbp-als.Differential_Diagnosis">Differential Diagnosis</a>). Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> and mitochondrial sequencing may be considered if single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) fails to confirm a diagnosis in an individual with features of ALS. For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><p><b>Other.</b> In some cases testing for other rare genetic causes of FALS can be considered, although these typically have a distinctive clinical presentation or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance pattern (see <a href="/books/n/gene/als-overview/">Amyotrophic Lateral Sclerosis Overview</a>).</p><p><b>Simplex/<a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> ALS (SALS) (i.e., single occurrence in a family)</b></p><p>Sequencing of <i>TARDBP</i> in SALS can be performed, but the lower mutation prevalence (1.1%) in this population should be taken into consideration.</p></div></div><div id="tardbp-als.Clinical_Characteristics"><h2 id="_tardbp-als_Clinical_Characteristics_">Clinical Characteristics</h2><div id="tardbp-als.Clinical_Description"><h3>Clinical Description</h3><p>More than 200 individuals with <i>TARDBP-</i>related ALS have been described in the literature. The spectrum of clinical disease has been defined by a recent analysis of all published reports of individuals with a <i>TARDBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, noting substantial differences between Asian and non-Asian individuals [<a class="bk_pop" href="#tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</a>].</p><p>The average age of symptom onset is 53.5 &#x000b1; 12.3 years (mean &#x000b1; SD), which is similar to <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with <i>SOD1</i> pathogenic variants but substantially earlier than those with <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS and <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS without an identified <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p>Most individuals with <i>TARDBP</i>-related ALS have both UMN and LMN involvement and during disease course will meet El Escorial criteria for ALS [<a class="bk_pop" href="#tardbp-als.REF.brooks.2000.293">Brooks et al 2000</a>]. Although predominantly LMN involvement is common [<a class="bk_pop" href="#tardbp-als.REF.gitcho.2008.535">Gitcho et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.k_hnlein.2008.1185">K&#x000fc;hnlein et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.corrado.2009.688">Corrado et al 2009</a>], no individuals with pure UMN involvement (i.e. primary lateral sclerosis) have been reported.</p><p>More than half of non-Asian individuals with a <i>TARDBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have first symptoms in the upper extremities, a rate that is double that found in other forms of the disease. However, bulbar onset appears to predominate in Asian individuals [<a class="bk_pop" href="#tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</a>] and intra- and <a class="def" href="/books/n/gene/glossary/def-item/interfamilial-variability/">interfamilial variability</a> in the site of onset is observed even with the same pathogenic variant (see <a href="#tardbp-als.GenotypePhenotype_Correlation">Genotype-Phenotype Correlations</a>).</p><p>As with other forms of ALS, individuals with <i>TARDBP-</i>related ALS die of respiratory failure when phrenic and thoracic motor neurons become severely involved. However, the median disease survival in non-Asian individuals with a <i>TARDBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 62 months, which is significantly longer than the survival of individuals without a known <i>TARDBP</i> pathogenic variant, either with <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS (35 months) or <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS (31 months). Interestingly, Asian individuals with a <i>TARDBP</i> pathogenic variant appear to have even slower rates of progression of disease, with median disease duration of 108 months [<a class="bk_pop" href="#tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</a>]. Disease duration is also influenced by which pathogenic variant is present, and although the median survival is favorable, progression to death within a year is not uncommon (see <a href="#tardbp-als.GenotypePhenotype_Correlation">Genotype-Phenotype Correlations</a>).</p><p>Although these trends are visible in aggregated cohorts of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, the range of age at onset, pattern of symptoms at onset, and disease duration are quite broad and substantially overlap with all other causes of ALS. As a result, phenotypic features do little to inform whether genetic testing should be pursued.</p></div><div id="tardbp-als.GenotypePhenotype_Correlation"><h3>Genotype-Phenotype Correlations</h3><p>Correlations between specific pathogenic variants and clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> are available for only the most commonly reported pathogenic variants in <i>TARDBP.</i> For the vast majority of pathogenic variants, the numbers are too few to draw reliable conclusions. However:</p><ul><li class="half_rhythm"><div>As predicted by early reports, the <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">p.Gly298Ser</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> demonstrates an earlier age of onset (mean 50.7 years) and the most rapid rate of progression of disease (mean 27 months) [<a class="bk_pop" href="#tardbp-als.REF.van_deerlin.2008.409">Van Deerlin et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</a>].</div></li><li class="half_rhythm"><div>The <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">p.Ala315Thr</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was initially reported in two families with a slowly progressive limb-only LMN-predominant <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#tardbp-als.REF.gitcho.2008.535">Gitcho et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</a>]. Large groups of individuals with this pathogenic variant now confirm a much later age at onset (mean 66 years) and much longer survival (mean 110 months) [<a class="bk_pop" href="#tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</a>].</div></li><li class="half_rhythm"><div>Other more common pathogenic variants including <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">p.Ala382Thr</a>, <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">p.Met337Val</a>, and <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">p.Gly348Cys</a> are intermediate in their average ages at onset and survival times [<a class="bk_pop" href="#tardbp-als.REF.corcia.2012.1519">Corcia et al 2012</a>].</div></li><li class="half_rhythm"><div>Within families, no <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been made with regard to site of onset, with both limb onset and bulbar onset being observed in the same family.</div></li><li class="half_rhythm"><div>Disparate sites of onset were seen in unrelated persons with the same <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, including the following: <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">p.Gly287Ser</a> [<a class="bk_pop" href="#tardbp-als.REF.corrado.2009.688">Corrado et al 2009</a>, <a class="bk_pop" href="#tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</a>], <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">p.Gly294Val</a> [<a class="bk_pop" href="#tardbp-als.REF.corrado.2009.688">Corrado et al 2009</a>, <a class="bk_pop" href="#tardbp-als.REF.del_bo.2009.727">Del Bo et al 2009</a>], and <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">p.Ala382Thr</a> [<a class="bk_pop" href="#tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</a>].</div></li></ul></div><div id="tardbp-als.Penetrance"><h3>Penetrance</h3><p>Like pathogenic variants in other ALS-related genes (e.g., <i>SOD1</i>), <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is clearly incomplete. This is evident from the number of individuals with apparently <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS who have a <i>TARDBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, which may have been inherited from an ostensibly asymptomatic (or undiagnosed) parent. However, accurate estimates are difficult to achieve for the following reasons:</p><ul><li class="half_rhythm"><div>Few unaffected individuals in families with <i>TARDBP</i>-related ALS have been genotyped or longitudinally followed for the emergence of symptoms.</div></li><li class="half_rhythm"><div>The parents and relatives of apparently <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> ALS cases with <i>TARDBP</i> pathogenic variants have not been reported in detail.</div></li></ul></div><div id="tardbp-als.Prevalence"><h3>Prevalence</h3><p>The prevalence of <i>TARDBP</i> pathogenic variants in:</p><ul><li class="half_rhythm"><div>All individuals with ALS (FALS and SALS) is 1.6% (49/3108 persons);</div></li><li class="half_rhythm"><div>FALS is 3.4% (21/618 probands), but ranges from 0% to 12% across studies [<a class="bk_pop" href="#tardbp-als.REF.gitcho.2008.535">Gitcho et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.gijselinck.2009.1329">Gijselinck et al 2009</a>];</div></li><li class="half_rhythm"><div>SALS is 1.1% but ranges from 0% to 5% across studies [<a class="bk_pop" href="#tardbp-als.REF.guerreiro.2008.e2450">Guerreiro et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</a>].</div></li></ul><p>Pathogenic variants in <i>TARDBP</i> have been reported worldwide:</p><ul><li class="half_rhythm"><div>North America [<a class="bk_pop" href="#tardbp-als.REF.gitcho.2008.535">Gitcho et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</a>]</div></li><li class="half_rhythm"><div>Europe [<a class="bk_pop" href="#tardbp-als.REF.k_hnlein.2008.1185">K&#x000fc;hnlein et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.sreedharan.2008.1668">Sreedharan et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.corrado.2009.688">Corrado et al 2009</a>, <a class="bk_pop" href="#tardbp-als.REF.daoud.2009.112">Daoud et al 2009</a>, <a class="bk_pop" href="#tardbp-als.REF.del_bo.2009.727">Del Bo et al 2009</a>]</div></li><li class="half_rhythm"><div>Japan [<a class="bk_pop" href="#tardbp-als.REF.yokoseki.2008.538">Yokoseki et al 2008</a>]</div></li><li class="half_rhythm"><div>China [<a class="bk_pop" href="#tardbp-als.REF.van_deerlin.2008.409">Van Deerlin et al 2008</a>]</div></li></ul><p>A higher prevalence in Italian, French, and Taiwanese populations has been reported [<a class="bk_pop" href="#tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.corrado.2009.688">Corrado et al 2009</a>, <a class="bk_pop" href="#tardbp-als.REF.daoud.2009.112">Daoud et al 2009</a>, <a class="bk_pop" href="#tardbp-als.REF.del_bo.2009.727">Del Bo et al 2009</a>]. The <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">p.Ala382Thr</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is very common in Sardinia due to a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a>. It accounts for 80% of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> ALS and 9% of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases [<a class="bk_pop" href="#tardbp-als.REF.orr_.2012.172">Orr&#x000f9; et al 2012</a>].</p></div></div><div id="tardbp-als.Genetically_Related_Allelic_D"><h2 id="_tardbp-als_Genetically_Related_Allelic_D_">Genetically Related (Allelic) Disorders</h2><p>Although typical ALS is the predominant <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> associated with <i>TARDBP</i> pathogenic variants, individuals with <i>TARDBP</i> pathogenic variants can also present with frontotemporal lobar degeneration with motor neuron disease (FTLD-MND) and rarely with frontotemporal dementia without motor neuron loss [<a class="bk_pop" href="#tardbp-als.REF.borroni.2010.509">Borroni et al 2010</a>, <a class="bk_pop" href="#tardbp-als.REF.synofzik.2014.1212.e1">Synofzik et al 2014</a>]. Because individuals with a <i>TARDBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can have some extrapyramidal symptoms, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has also identified a few individuals with parkinsonism but no motor neuron loss [<a class="bk_pop" href="#tardbp-als.REF.rayaprolu.2013.312">Rayaprolu et al 2013</a>].</p></div><div id="tardbp-als.Differential_Diagnosis"><h2 id="_tardbp-als_Differential_Diagnosis_">Differential Diagnosis</h2><p>For a detailed discussion of these disorders and the differential diagnosis of ALS, see <a href="/books/n/gene/als-overview/">Amyotrophic Lateral Sclerosis Overview</a>.</p><p><i>TARDBP</i>-associated ALS must be differentiated from conditions that have overlapping features of ALS. Detailed clinical evaluation (as outlined above) is usually sufficient to exclude other disorders. The rate of misdiagnosis in ALS is highest in individuals presenting with purely LMN findings [<a class="bk_pop" href="#tardbp-als.REF.traynor.2000.109">Traynor et al 2000</a>].</p><p>The mimics of ALS from any cause are numerous and include:</p><ul><li class="half_rhythm"><div>Multifocal motor neuropathy</div></li><li class="half_rhythm"><div>Cervical spondylosis</div></li><li class="half_rhythm"><div>Adult-onset <a href="/books/n/gene/sma/">spinal muscular atrophy</a> (SMA)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/kennedy/">Kennedy disease</a> (<a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> spinobulbar muscular atrophy [SBMA])</div></li><li class="half_rhythm"><div>Acquired and hereditary motor neuropathies (see <a href="/books/n/gene/cmt/">Charcot-Marie-Tooth Hereditary Neuropathy Overview</a>)</div></li><li class="half_rhythm"><div>Late-onset GM2 gangliosidosis (see <a href="/books/n/gene/tay-sachs/">Hexosaminidase A Deficiency</a>)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/apbd/">Adult polyglucosan body disease</a></div></li></ul><p>The number of other genes associated with FALS (see Note) has been rapidly increasing and is tracked at the <a href="http://alsod.iop.kcl.ac.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALSoD site</a>. Some examples:</p><ul><li class="half_rhythm"><div>ALS1. <i>SOD1</i> (encoding the protein superoxide dismutase)</div></li><li class="half_rhythm"><div>ALS4. <i>SETX</i> (encoding the protein probable helicase senataxin)</div></li><li class="half_rhythm"><div>ALS6. <i>FUS/TLS</i> (encoding the protein )</div></li><li class="half_rhythm"><div>ALS8. <i>VAPB</i> (encoding the protein vesicle-associated membrane protein-associated protein B/C)</div></li><li class="half_rhythm"><div>ALS9. <i>ANG</i> (encoding the protein angiogenin)</div></li><li class="half_rhythm"><div><i>DCTN1</i> (encoding the protein dynactin subunit 1)</div></li></ul><p>Note: Pathogenic variants in many of these genes have also been identified in small numbers of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases of ALS (i.e., a single occurrence in a family).</p></div><div id="tardbp-als.Management"><h2 id="_tardbp-als_Management_">Management</h2><div id="tardbp-als.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <i>TARDBP</i>-related ALS (or any other form of ALS), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>EMG/NCS to document the regions of involvement</div></li><li class="half_rhythm"><div>Pulmonary function testing to detect and stage respiratory involvement</div></li><li class="half_rhythm"><div>Speech and swallowing evaluation if dysarthria and/or dysphagia are present, to direct care to minimize risk of aspiration and to initiate augmentative communication strategies for possible loss of verbal communication</div></li><li class="half_rhythm"><div>Physical and occupational therapy evaluation to determine what adaptive devices are needed to maximize function</div></li><li class="half_rhythm"><div>Nutritional evaluation</div></li><li class="half_rhythm"><div>Screening for depression and need for psychosocial support</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="tardbp-als.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The management of <i>TARDBP</i>-related ALS is identical to that of ALS resulting from other causes, and is outlined in the American Academy of Neurology practice parameter on this topic [<a class="bk_pop" href="#tardbp-als.REF.miller.2009a.1218">Miller et al 2009a</a>, <a class="bk_pop" href="#tardbp-als.REF.miller.2009b.1227">Miller et al 2009b</a>].</p><ul><li class="half_rhythm"><div>Spasticity can be treated with a spasmolytic such as baclofen or a benzodiazepine.</div></li><li class="half_rhythm"><div>Pseudobulbar affect can be treated with a tricyclic antidepressant or combination of quinidine and dextromethorphan.</div></li><li class="half_rhythm"><div>Sialorrhea is often managed with anticholinergic medications (tricyclic antidepressants, scopolamine, atropine drops) or botulinum toxin injection of the salivary glands.</div></li><li class="half_rhythm"><div>Antidepressants are often required to treat concurrent depression.</div></li><li class="half_rhythm"><div>Riluzole is the only FDA-approved treatment for any type of ALS. Although there are no efficacy data specifically for <i>TARDBP</i>-related ALS, strong consideration should be given to its use [<a class="bk_pop" href="#tardbp-als.REF.miller.2007.cd001447">Miller et al 2007</a>].</div></li></ul><p>Note: See <a href="#tardbp-als.Author_Notes">Author Notes</a>, Miller Laboratory for a link to investigative reports on accurate assessments of the risks and benefits of specific proposed therapies.</p></div><div id="tardbp-als.Prevention_of_Secondary_Compl"><h3>Prevention of Secondary Complications</h3><p>Adequate nutrition and weight maintenance are essential. Percutaneous gastrostomy is often appropriate to maintain adequate caloric intake in persons with significant bulbar involvement.</p><p>Joint contractures can occur, are often painful, and can interfere with care giving. Appropriate bracing and stretching can minimize contractures.</p><p>Early initiation of noninvasive ventilation has been shown to prolong survival [<a class="bk_pop" href="#tardbp-als.REF.farrero.2005.2132">Farrero et al 2005</a>].</p></div><div id="tardbp-als.Surveillance"><h3>Surveillance</h3><p>Monitoring of the forced vital capacity and other parameters of ventilation should be performed at clinic visits to determine the appropriate time to offer noninvasive ventilation.</p><p>Routine screening for depression at clinic visits is appropriate.</p></div><div id="tardbp-als.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Long-term use of minocycline, which was studied in a randomized-controlled trial in individuals with ALS, was associated with worse outcomes [<a class="bk_pop" href="#tardbp-als.REF.gordon.2007.1045">Gordon et al 2007</a>].</p><p>Excessive exercise to the point of inducing fatigue in already weakened muscles is cautioned against by many practitioners based on experience.</p></div><div id="tardbp-als.Evaluation_of_Relatives_at_Ri"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#tardbp-als.Related_Genetic_Counseling_Is">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="tardbp-als.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>While no current clinical trials are specifically designed to target <i>TARDBP</i>-related ALS, many ongoing trials address the broader category of ALS.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="tardbp-als.Genetic_Counseling"><h2 id="_tardbp-als_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="tardbp-als.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>TARDBP</i>-related amyotrophic lateral sclerosis is usually inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. In very rare instances, an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual may have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>TARDBP</i> [<a class="bk_pop" href="#tardbp-als.REF.borghero.2011.2327.e1">Borghero et al 2011</a>] or may have <a class="def" href="/books/n/gene/glossary/def-item/digenic/">digenic</a> pathogenic variants (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TARDBP</i> with a coexisting repeat expansion in <i>C9ORF72</i> [<a class="bk_pop" href="#tardbp-als.REF.van_blitterswijk.2012.3776">van Blitterswijk et al 2012</a>]).</p></div><div id="tardbp-als.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Many individuals diagnosed with <i>TARDBP</i>-related ALS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <i>TARDBP</i>-related ALS may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The frequency of <i>TARDBP de novo</i> pathogenic variants is unknown because relatives of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases have not been sufficiently evaluated to exclude low <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, two possible explanations are <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent or a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent de novo <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include thorough neurologic evaluation and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>TARDBP</i> pathogenic variant identified in the proband. Evaluation of parents may determine that one is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but has escaped previous diagnosis because of failure by health care professionals to recognize the syndrome and/or a milder phenotypic presentation. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed on the parents of the proband.</div></li></ul><p>Note: (1) Although most individuals diagnosed with TARDBP-related ALS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset or reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of the disease in the affected parent. (2) If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the pathogenic variant and may be mildly/minimally affected.</p><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs of inheriting the <i>TARDBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 50%.</div></li><li class="half_rhythm"><div>The sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically unaffected parents are still at increased risk (for the disorder) because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low, but greater than that of the general population, because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with <i>TARDBP</i>-related ALS has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to other family members depends on the status of the proband's parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <i>TARDBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="tardbp-als.Related_Genetic_Counseling_Is"><h3>Related Genetic Counseling Issues</h3><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the pathogenic variant occurred <i>de novo</i> in the proband. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Testing of at-risk asymptomatic adults.</b> Presymptomatic testing for a <i>TARDBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is complicated because the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is unknown, the age of onset is not predictable, and preventive measures do not exist. Because of the individualized nature of predictive testing, consultation with a genetic counselor and a psychologist to obtain informed consent is recommended. At this time, no established testing protocol (e.g., as in <a href="/books/n/gene/huntington/">Huntington disease</a>) exists, although establishment of such protocols has been suggested. However, to err on the side of caution, testing centers often follow a similar protocol.</p><p><b>Testing of at-risk individuals during childhood.</b> Consensus holds that asymptomatic individuals younger than age 18 years who are at risk for adult-onset disorders should not have <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. The principal reasons against testing such individuals are that testing removes their choice to know or not know this information, it raises the possibility of stigmatization within the family and in other social settings, and it could have serious educational and career implications. In addition, no preventive treatment is available for ALS. See also the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p><p>Individuals younger than age 18 years who are symptomatic usually benefit from having a specific diagnosis established.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk is before pregnancy. Similarly, decisions about testing to determine the genetic status of at-risk asymptomatic family members are best made before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="tardbp-als.Prenatal_Testing_and_Preimpla"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>TARDBP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for <i>TARDBP</i>-related ALS are possible.</p><p>Requests for prenatal testing for adult-onset conditions (like <i>TARDBP</i>-related ALS) are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although decisions about prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="tardbp-als.Resources"><h2 id="_tardbp-als_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Amyotrophic Lateral Sclerosis Association (ALS Association)</b></div><div>27001 Agoura Road</div><div>Suite 250</div><div>Calabasas Hills CA 91301-5104</div><div><b>Phone:</b> 800-782-4747 (Toll-free Patient Services); 818-880-9007</div><div><b>Fax:</b> 818-880-9006</div><div><b>Email:</b> alsinfo@alsa-national.org</div><div><a href="http://www.alsa.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.alsa.org</a></div></li><li class="half_rhythm"><div><b>Amyotrophic Lateral Sclerosis Society of Canada</b></div><div>3000 Steeles Avenue East</div><div>Suite 200</div><div>Markham Ontario L3R 4T9</div><div>Canada</div><div><b>Phone:</b> 800-267-4257 (toll-free); 905-248-2052</div><div><b>Fax:</b> 905-248-2019</div><div><a href="http://www.als.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.als.ca</a></div></li><li class="half_rhythm"><div><b>Les Turner ALS Foundation (Amyotrophic Lateral Sclerosis)</b></div><div>5550 West Touhy Avenue</div><div>Suite 302</div><div>Skokie IL 60077-3254</div><div><b>Phone:</b> 888-257-1107 (toll-free); 847-679-3311</div><div><b>Fax:</b> 847-679-9109</div><div><b>Email:</b> info@lesturnerals.org</div><div><a href="http://www.lesturnerals.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.lesturnerals.org</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA-ALS Division)</b></div><div>222 S. Riverside Plaza </div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-344-4863 (toll-free); 800-572-1717 (toll-free)</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="https://www.mda.org/sites/default/files/MDA-ALS-Fact-Sheet-Flyer-FINAL.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org/sites/default/files/MDA-ALS-Fact-Sheet-Flyer-FINAL.pdf</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/amyotrophic-lateral-sclerosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Amyotrophic lateral sclerosis</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22225/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Amyotrophic lateral sclerosis</a></div></li></ul></div><div id="tardbp-als.Molecular_Genetics"><h2 id="_tardbp-als_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="tardbp-als.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>TARDBP-Related Amyotrophic Lateral Sclerosis: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5942/table/tardbp-als.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tardbp-als.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_tardbp-als.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Locus Name</th><th id="hd_b_tardbp-als.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_tardbp-als.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_tardbp-als.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_tardbp-als.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_tardbp-als.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_tardbp-als.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_tardbp-als.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">ALS10</td><td headers="hd_b_tardbp-als.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/23435" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TARDBP</i></a></td><td headers="hd_b_tardbp-als.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=23435" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1p36<wbr style="display:inline-block"></wbr>​.22</a></td><td headers="hd_b_tardbp-als.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q13148" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TAR DNA-binding protein 43</a></td><td headers="hd_b_tardbp-als.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://reseq.biosciencedbc.jp/resequence/GeneDetail.do?targetId=1&#x00026;geneId=EG23435" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALS mutation database (TARDBP)</a><br /><a href="http://databases.lovd.nl/shared/genes/TARDBP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TARDBP database</a></td><td headers="hd_b_tardbp-als.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TARDBP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TARDBP</a></td><td headers="hd_b_tardbp-als.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TARDBP[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TARDBP</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="tardbp-als.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="tardbp-als.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for TARDBP-Related Amyotrophic Lateral Sclerosis (<a href="/omim/605078,612069" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5942/table/tardbp-als.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tardbp-als.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605078" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605078</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TAR DNA-BINDING PROTEIN; TARDBP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/612069" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">612069</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AMYOTROPHIC LATERAL SCLEROSIS 10 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS10</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>TARDBP</i> has six exons, five of which are coding. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK5942/#tardbp-als.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 35 <i>TARDBP</i> coding variants have been identified in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> (FALS) and/or <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases of ALS (SALS). The majority of these variants have been identified in single simplex cases or in probands of families for which <a class="def" href="/books/n/gene/glossary/def-item/segregation/">segregation</a> data are unavailable. The argument for the pathogenicity of these variants has historically stood on their location (within <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 6 near clearly causative pathogenic variants) and their absence in control subjects (usually a modest number). This fact could suggest a high percentage of <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a> (i.e., unique) variants in <i>TARDBP-</i>related ALS [<a class="bk_pop" href="#tardbp-als.REF.corrado.2009.688">Corrado et al 2009</a>].</p><p>However, <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> in large non-ALS populations, such as the 1000 Genomes Project or ExAC browser, have identified infrequent and rare coding variants across <i>TARDBP,</i> including some within <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 6. In fact, six variants previously identified in patients with ALS are now found in these databases (but always in &#x0003c;1 in 30,000 individuals). Determining the significance of this group of variants is difficult in the absence of additional genetic data (e.g., additional cases or <a class="def" href="/books/n/gene/glossary/def-item/segregation/">segregation</a> within a family). A clear classification as pathogenic or benign may not be possible until functional assays are developed that reliably distinguish between these groups.</p><p>Evidence for pathogenicity is much clearer for a minority of published variants (<a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">Table 2</a>). Some have been found in more than one family or <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (p.Asn267Ser; p.Gly287Ser; p.Ala315Thr; p.Met337Val; p.Asn352Ser) or have been found in both FALS and SALS cases (p.Gly294Val; p.Gly295Ser; p.Gly348Cys; p.Ala382Thr). All clearly pathogenic variants affect highly conserved amino acids and reside in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 6. This finding may be biased because exon 6 has often been selectively resequenced.</p><p>Two non-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 6 variants are <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">p.Asp169Gly</a> (in exon 4) [<a class="bk_pop" href="#tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</a>] and the 3&#x02019; UTR variant <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">1462T&#x0003e;C</a> [<a class="bk_pop" href="#tardbp-als.REF.daoud.2009.112">Daoud et al 2009</a>]. However, each has been found in only one individual with SALS, making it unclear if these are truly pathogenic. Only one pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant has been described to date (a single base-pair <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>-producing frameshift and a premature stop codon p.Tyr374Ter [<a class="bk_pop" href="#tardbp-als.REF.daoud.2009.112">Daoud et al 2009</a>]).</p><p><b>Benign variants.</b> Given the complexities of distinguishing benign from pathogenic rare variants, the interpretation of the p.Ala90Val variant has been particularly challenging. The <a class="figpopup" href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figtardbpalsTtardbpvariantsdiscussedi" rid-ob="figobtardbpalsTtardbpvariantsdiscussedi">p.Ala90Val</a> variant was originally found in an individual with FTLD-MND [<a class="bk_pop" href="#tardbp-als.REF.winton.2008.2252">Winton et al 2008</a>], but has subsequently been seen in other patient cohorts. However, it is also consistently found in controls of northern European background as well [<a class="bk_pop" href="#tardbp-als.REF.guerreiro.2008.e2450">Guerreiro et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.kabashi.2008.572">Kabashi et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.sreedharan.2008.1668">Sreedharan et al 2008</a>]. By genetic evidence alone, it is therefore likely to be benign. However, experimental data suggest that this <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> causes abnormal cytoplasmic aggregation of TDP-43 [<a class="bk_pop" href="#tardbp-als.REF.winton.2008.2252">Winton et al 2008</a>], and therefore it remains possible that the p.Ala90Val substitution may convey susceptibility to developing FTD/ALS.</p><div id="tardbp-als.T.tardbp_variants_discussed_i" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p><i>TARDBP</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5942/table/tardbp-als.T.tardbp_variants_discussed_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tardbp-als.T.tardbp_variants_discussed_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Uncertain Significance</b></td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.269C&#x0003e;T</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala90Val&#x000a0;<sup>2,&#x000a0;3</sup></td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_4" rowspan="14" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/42741653" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_007375<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/6678271" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_031401<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.506A&#x0003e;G</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp169Gly</td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1121dup</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr374Ter</td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.*83T&#x0003e;C&#x000a0;<sup>4</sup><br />(1462T&#x0003e;C)</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(3&#x02019; untranslated region)</td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_1" rowspan="10" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.800A&#x0003e;G</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn267Ser&#x000a0;<sup>3,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.859G&#x0003e;A</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly287Ser&#x000a0;<sup>3,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.881G&#x0003e;T</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly294Val&#x000a0;<sup>3,&#x000a0;6,&#x000a0;7</sup></td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.883G&#x0003e;A</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly295Ser&#x000a0;<sup>6,&#x000a0;7</sup></td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.892G&#x0003e;A</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly298Ser&#x000a0;<sup>5,&#x000a0;7</sup></td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.943G&#x0003e;A</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala315Thr&#x000a0;<sup>5,&#x000a0;8</sup></td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1009A&#x0003e;G</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met337Val&#x000a0;<sup>5,&#x000a0;8</sup></td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1042G&#x0003e;T</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly348Cys&#x000a0;<sup>5,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1055A&#x0003e;G</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn352Ser&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1144G&#x0003e;A</td><td headers="hd_h_tardbp-als.T.tardbp_variants_discussed_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala382Thr&#x000a0;<sup>5,&#x000a0;6,&#x000a0;9</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="tardbp-als.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="tardbp-als.TF.2.2"><p class="no_margin">May be a variant that is normal or may confer susceptibility to FTD/ALS</p></div></dd><dt>3. </dt><dd><div id="tardbp-als.TF.2.3"><p class="no_margin">Variant is also rarely found in population controls.</p></div></dd><dt>4. </dt><dd><div id="tardbp-als.TF.2.4"><p class="no_margin">* indicates location in 3&#x02019;UTR and number of nucleotides beyond the normal stop codon.</p></div></dd><dt>5. </dt><dd><div id="tardbp-als.TF.2.5"><p class="no_margin">Identified in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in more than one family</p></div></dd><dt>6. </dt><dd><div id="tardbp-als.TF.2.6"><p class="no_margin">Identified in both FALS and SALS</p></div></dd><dt>7. </dt><dd><div id="tardbp-als.TF.2.7"><p class="no_margin">Limited evidence of <a class="def" href="/books/n/gene/glossary/def-item/segregation/">segregation</a></p></div></dd><dt>8. </dt><dd><div id="tardbp-als.TF.2.8"><p class="no_margin">Convincing evidence of <a class="def" href="/books/n/gene/glossary/def-item/segregation/">segregation</a></p></div></dd><dt>9. </dt><dd><div id="tardbp-als.TF.2.9"><p class="no_margin">Familial and <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases share founder haplotype.</p></div></dd></dl></div></div></div><p>See <a href="/books/NBK5942/bin/tardbp-als-Table3.pdf">Table 3</a> (pdf) for a more complete list of <i>TARDBP</i> variants of uncertain clinical significance.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> TDP-43 comprises 414 amino acids encoded by <i>TARDBP</i> exons 2-6. TDP-43 is a ubiquitously expressed nuclear protein with structural similarities to the hnRNP A/B family of RNA binding proteins and is known to regulate DNA transcription, alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>, and <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> stability [<a class="bk_pop" href="#tardbp-als.REF.buratti.2008.867">Buratti &#x00026; Baralle 2008</a>]. Although information regarding the role of TDP-43 in normal cellular function is limited, both loss of function and overexpression are deleterious in a wide variety of cellular contexts in vitro and in vivo [<a class="bk_pop" href="#tardbp-als.REF.baloh.2011.3539">Baloh 2011</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Most of the clearly pathogenic variants thus far identified are located in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 6. These cluster in the C-terminal glycine-rich <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of the TDP-43, an area that interacts with other hnRNPs to regulate alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> [<a class="bk_pop" href="#tardbp-als.REF.buratti.2005.37572">Buratti et al 2005</a>] but is also critically involved in TDP-43 self-aggregation and has properties similar to prion-related domains in yeast [<a class="bk_pop" href="#tardbp-als.REF.cushman.2010.1191">Cushman et al 2010</a>, <a class="bk_pop" href="#tardbp-als.REF.udan.2011.1">Udan &#x00026; Baloh 2011</a>]. In <i>TARDBP</i>-related ALS, TDP-43 positive aggregates are phosphorylated and ubiquitinated, and are present in both the cytoplasm and the nucleus. Because a decrease in normal nuclear TDP-43 staining is often seen in these cells, loss of function has also been proposed to play a role in disease [<a class="bk_pop" href="#tardbp-als.REF.neumann.2006.130">Neumann et al 2006</a>, <a class="bk_pop" href="#tardbp-als.REF.davidson.2007.521">Davidson et al 2007</a>]. While pathogenic variants in <i>TARDBP</i> have been shown to influence TDP-43 proteolysis and aggregation, the exact role they play in promoting ALS remains poorly understood [<a class="bk_pop" href="#tardbp-als.REF.baloh.2012.701">Baloh 2012</a>].</p><p>Importantly, TDP-43 positive inclusions are not specific to ALS, and are found in numerous other neurodegenerative diseases [<a class="bk_pop" href="#tardbp-als.REF.freeman.2008.62">Freeman et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.uryu.2008.555">Uryu et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.arai.2009.125">Arai et al 2009</a>] as well as several diseases of muscle [<a class="bk_pop" href="#tardbp-als.REF.weihl.2008.1186">Weihl et al 2008</a>, <a class="bk_pop" href="#tardbp-als.REF.k_sters.2009.209">K&#x000fc;sters et al 2009</a>, <a class="bk_pop" href="#tardbp-als.REF.oliv_.2009.262">Oliv&#x000e9; et al 2009</a>].</p></div><div id="tardbp-als.References"><h2 id="_tardbp-als_References_">References</h2><div id="tardbp-als.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.arai.2009.125">Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, Iritani S, Onaya M, Akiyama H. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. <span><span class="ref-journal">Acta Neuropathol. </span>2009;<span class="ref-vol">117</span>:125–36.</span> [<a href="/pubmed/19139911" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19139911</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.baloh.2011.3539">Baloh RH. TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. <span><span class="ref-journal">FEBS J. </span>2011;<span class="ref-vol">278</span>:3539–49.</span> [<a href="/pmc/articles/PMC3177991/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3177991</span></a>] [<a href="/pubmed/21777387" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21777387</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.baloh.2012.701">Baloh RH. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other? <span><span class="ref-journal">Curr Opin Neurol. </span>2012;<span class="ref-vol">25</span>:701–7.</span> [<a href="/pubmed/23041957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23041957</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.b_umer.2009.1283">B&#x000e4;umer D, Parkinson N, Talbot K. TARDBP in amyotrophic lateral sclerosis: identification of a novel variant but absence of copy number variation. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2009;<span class="ref-vol">80</span>:1283–5.</span> [<a href="/pubmed/19864663" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19864663</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.benajiba.2009.470">Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion C, Couratier P, Legallic S, Salachas F, Hannequin D, Decousus M, Lacomblez L, Guedj E, Golfier V, Camu W, Dubois B, Campion D, Meininger V, Brice A., French Clinical and Genetic Research Network on Frontotemporal Lobar Degeneration/Frontotemporal Lobar Degeneration with Motoneuron Disease.  TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. <span><span class="ref-journal">Ann Neurol. </span>2009;<span class="ref-vol">65</span>:470–3.</span> [<a href="/pubmed/19350673" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19350673</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.borghero.2011.2327.e1">Borghero G, Floris G, Cannas A, Marrosu MG, Murru MR, Costantino E, Parish LD, Pugliatti M, Ticca A, Traynor BJ, Calvo A, Cammarosano S, Moglia C, Cistaro A, Brunetti M, Restagno G, Chi&#x000f2; A. A patient carrying a homozygous p.A382T TARDBP missense mutation shows a syndrome including ALS, extrapyramidal symptoms, and FTD. <span><span class="ref-journal">Neurobiol Aging. </span>2011;<span class="ref-vol">32</span>:2327.e1–5.</span> [<a href="/pmc/articles/PMC3192246/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3192246</span></a>] [<a href="/pubmed/21803454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21803454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.borroni.2010.509">Borroni B, Archetti S, Del Bo R, Papetti A, Buratti E, Bonvicini C, Agosti C, Cosseddu M, Turla M, Di Lorenzo D, Pietro Comi G, Gennarelli M, Padovani A. TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. <span><span class="ref-journal">Rejuvenation Res. </span>2010;<span class="ref-vol">13</span>:509–17.</span> [<a href="/pubmed/20645878" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20645878</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.brooks.2000.293">Brooks BR, Miller RG, Swash M, Munsat TL., World Federation of Neurology Research Group on Motor Neuron Diseases.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. <span><span class="ref-journal">Amyotroph Lateral Scler Other Motor Neuron Disord. </span>2000;<span class="ref-vol">1</span>:293–9.</span> [<a href="/pubmed/11464847" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11464847</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.buratti.2008.867">Buratti E, Baralle FE. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. <span><span class="ref-journal">Front Biosci. </span>2008;<span class="ref-vol">13</span>:867–78.</span> [<a href="/pubmed/17981595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17981595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.buratti.2005.37572">Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. <span><span class="ref-journal">J Biol Chem. </span>2005;<span class="ref-vol">280</span>:37572–84.</span> [<a href="/pubmed/16157593" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16157593</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.corcia.2012.1519">Corcia P, Valdmanis P, Millecamps S, Lionnet C, Blasco H, Mouzat K, Daoud H, Belzil V, Morales R, Pageot N, Danel-Brunaud V, Vandenberghe N, Pradat PF, Couratier P, Salachas F, Lumbroso S, Rouleau GA, Meininger V, Camu W. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. <span><span class="ref-journal">Neurology. </span>2012;<span class="ref-vol">78</span>:1519–26.</span> [<a href="/pubmed/22539580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22539580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.corrado.2009.688">Corrado L, Ratti A, Gellera C, Buratti E, Castellotti B, Carlomagno Y, Ticozzi N, Mazzini L, Testa L, Taroni F, Baralle FE, Silani V, D'Alfonso S. High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:688–94.</span> [<a href="/pubmed/19224587" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19224587</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.cushman.2010.1191">Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. Prion-like disorders: blurring the divide between transmissibility and infectivity. <span><span class="ref-journal">J Cell Sci. </span>2010;<span class="ref-vol">123</span>:1191–201.</span> [<a href="/pmc/articles/PMC2848109/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2848109</span></a>] [<a href="/pubmed/20356930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20356930</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.daoud.2009.112">Daoud H, Valdmanis PN, Kabashi E, Dion P, Dupr&#x000e9; N, Camu W, Meininger V, Rouleau GA. Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. <span><span class="ref-journal">J Med Genet. </span>2009;<span class="ref-vol">46</span>:112–4.</span> [<a href="/pubmed/18931000" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18931000</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.davidson.2007.521">Davidson Y, Kelley T, Mackenzie IR, Pickering-Brown S, Du Plessis D, Neary D, Snowden JS, Mann DM. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. <span><span class="ref-journal">Acta Neuropathol. </span>2007;<span class="ref-vol">113</span>:521–33.</span> [<a href="/pubmed/17219193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17219193</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.del_bo.2009.727">Del Bo R, Ghezzi S, Corti S, Pandolfo M, Ranieri M, Santoro D, Ghione I, Prelle A, Orsetti V, Mancuso M, Sorar&#x000f9; G, Briani C, Angelini C, Siciliano G, Bresolin N, Comi GP. TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. <span><span class="ref-journal">Eur J Neurol. </span>2009;<span class="ref-vol">16</span>:727–32.</span> [<a href="/pubmed/19236453" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19236453</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.farrero.2005.2132">Farrero E, Prats E, Povedano M, Martinez-Matos JA, Manresa F, Escarrabill J. Survival in amyotrophic lateral sclerosis with home mechanical ventilation: the impact of systematic respiratory assessment and bulbar involvement. <span><span class="ref-journal">Chest. </span>2005;<span class="ref-vol">127</span>:2132–8.</span> [<a href="/pubmed/15947331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15947331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.floris.2015.375">Floris G, Borghero G, Cannas A, Di Stefano F, Murru MR, Corongiu D, Cuccu S, Tranquilli S, Cherchi MV, Serra A, Loi G, Marrosu MG, Chi&#x000f2; A, Marrosu F. Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations. <span><span class="ref-journal">J Neurol. </span>2015;<span class="ref-vol">262</span>:375–84.</span> [<a href="/pubmed/25408367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25408367</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.freeman.2008.62">Freeman SH, Spires-Jones T, Hyman BT, Growdon JH, Frosch MP. TAR-DNA binding protein 43 in Pick disease. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2008;<span class="ref-vol">67</span>:62–7.</span> [<a href="/pubmed/18091558" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18091558</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.gijselinck.2009.1329">Gijselinck I, Sleegers K, Engelborghs S, Robberecht W, Martin JJ, Vandenberghe R, Sciot R, Dermaut B, Goossens D, van der Zee J, De Pooter T, Del-Favero J, Santens P, De Jonghe P, De Deyn PP, Van Broeckhoven C, Cruts M. Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS. <span><span class="ref-journal">Neurobiol Aging. </span>2009;<span class="ref-vol">30</span>:1329–31.</span> [<a href="/pubmed/18068872" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18068872</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.gitcho.2008.535">Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, Hatanpaa KJ, White CL 3rd, Bigio EH, Caselli R, Baker M, Al-Lozi MT, Morris JC, Pestronk A, Rademakers R, Goate AM, Cairns NJ. TDP-43 A315T mutation in familial motor neuron disease. <span><span class="ref-journal">Ann Neurol. </span>2008;<span class="ref-vol">63</span>:535–8.</span> [<a href="/pmc/articles/PMC2747362/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2747362</span></a>] [<a href="/pubmed/18288693" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18288693</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.gordon.2007.1045">Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R., Western ALS Study Group.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. <span><span class="ref-journal">Lancet Neurol. </span>2007;<span class="ref-vol">6</span>:1045–53.</span> [<a href="/pubmed/17980667" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17980667</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.grosskreutz.2008.238">Grosskreutz J, Peschel T, Unrath A, Dengler R, Ludolph AC, Kassubek J. Whole brain-based computerized neuroimaging in ALS and other motor neuron disorders. <span><span class="ref-journal">Amyotroph Lateral Scler. </span>2008;<span class="ref-vol">9</span>:238–48.</span> [<a href="/pubmed/18608107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18608107</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.guerreiro.2008.e2450">Guerreiro RJ, Schymick JC, Crews C, Singleton A, Hardy J, Traynor BJ. TDP-43 is not a common cause of sporadic amyotrophic lateral sclerosis. <span><span class="ref-journal">PLoS ONE. </span>2008;<span class="ref-vol">3</span>:e2450.</span> [<a href="/pmc/articles/PMC2408729/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2408729</span></a>] [<a href="/pubmed/18545701" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18545701</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.kabashi.2008.572">Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, Pradat PF, Camu W, Meininger V, Dupre N, Rouleau GA. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. <span><span class="ref-journal">Nat Genet. </span>2008;<span class="ref-vol">40</span>:572–4.</span> [<a href="/pubmed/18372902" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18372902</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.kasai.2009.55">Kasai T, Tokuda T, Ishigami N, Sasayama H, Foulds P, Mitchell DJ, Mann DM, Allsop D, Nakagawa M. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. <span><span class="ref-journal">Acta Neuropathol. </span>2009;<span class="ref-vol">117</span>:55–62.</span> [<a href="/pubmed/18989684" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18989684</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.k_hnlein.2008.1185">K&#x000fc;hnlein P, Sperfeld AD, Vanmassenhove B, Van Deerlin V, Lee VM, Trojanowski JQ, Kretzschmar HA, Ludolph AC, Neumann M. Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. <span><span class="ref-journal">Arch Neurol. </span>2008;<span class="ref-vol">65</span>:1185–9.</span> [<a href="/pmc/articles/PMC2742976/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2742976</span></a>] [<a href="/pubmed/18779421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18779421</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.k_sters.2009.209">K&#x000fc;sters B, van Hoeve BJ, Schelhaas HJ, Ter Laak H, van Engelen BG, Lammens M. TDP-43 accumulation is common in myopathies with rimmed vacuoles. <span><span class="ref-journal">Acta Neuropathol. </span>2009;<span class="ref-vol">117</span>:209–11.</span> [<a href="/pubmed/19066918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19066918</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.miller.2009a.1218">Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC., Quality Standards Subcommittee of the American Academy of Neurology.  Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. <span><span class="ref-journal">Neurology. </span>2009a;<span class="ref-vol">73</span>:1218–26.</span> [<a href="/pmc/articles/PMC2764727/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2764727</span></a>] [<a href="/pubmed/19822872" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19822872</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.miller.2009b.1227">Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC., Quality Standards Subcommittee of the American Academy of Neurology.  Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment(an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. <span><span class="ref-journal">Neurology. </span>2009b;<span class="ref-vol">73</span>:1227–33.</span> [<a href="/pmc/articles/PMC2764728/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2764728</span></a>] [<a href="/pubmed/19822873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19822873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.miller.2007.cd001447">Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2007;<span class="ref-vol">3</span>:CD001447.</span> [<a href="/pubmed/17253460" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17253460</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.neumann.2006.130">Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. <span><span class="ref-journal">Science. </span>2006;<span class="ref-vol">314</span>:130–3.</span> [<a href="/pubmed/17023659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17023659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.nozaki.2010.1209">Nozaki I, Arai M, Takahashi K, Hamaguchi T, Yoshikawa H, Muroishi T, Noguchi-Shinohara M, Ito H, Itokawa M, Akiyama H, Kawata A, Yamada M. Familial ALS with G298S mutation in TARDBP: a comparison of CSF tau protein levels with those in sporadic ALS. <span><span class="ref-journal">Intern Med. </span>2010;<span class="ref-vol">49</span>:1209–12.</span> [<a href="/pubmed/20558945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20558945</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.oliv_.2009.262">Oliv&#x000e9; M, Janu&#x000e9; A, Moreno D, G&#x000e1;mez J, Torrej&#x000f3;n-Escribano B, Ferrer I. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2009;<span class="ref-vol">68</span>:262–73.</span> [<a href="/pubmed/19225410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19225410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.orr_.2012.172">Orr&#x000f9; S, Manolakos E, Orr&#x000f9; N, Kokotas H, Mascia V, Carcassi C, Petersen MB. High frequency of the TARDBP p.Ala382Thr mutation in Sardinian patients with amyotrophic lateral sclerosis. <span><span class="ref-journal">Clin Genet. </span>2012;<span class="ref-vol">81</span>:172–8.</span> [<a href="/pubmed/21418058" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21418058</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.pamphlett.2009.222">Pamphlett R, Luquin N, McLean C, Jew SK, Adams L. TDP-43 neuropathology is similar in sporadic amyotrophic lateral sclerosis with or without TDP-43 mutations. <span><span class="ref-journal">Neuropathol Appl Neurobiol. </span>2009;<span class="ref-vol">35</span>:222–5.</span> [<a href="/pubmed/18986339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18986339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.rayaprolu.2013.312">Rayaprolu S, Fujioka S, Traynor S, Soto-Ortolaza AI, Petrucelli L, Dickson DW, Rademakers R, Boylan KB, Graff-Radford NR, Uitti RJ, Wszolek ZK, Ross OA. TARDBP mutations in Parkinson's disease. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2013;<span class="ref-vol">19</span>:312–5.</span> [<a href="/pmc/articles/PMC3582838/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3582838</span></a>] [<a href="/pubmed/23231971" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23231971</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.rutherford.2008.e1000193">Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ, Kuntz K, Crook RJ, Sreedharan J, Vance C, Sorenson E, Lippa C, Bigio EH, Geschwind DH, Knopman DS, Mitsumoto H, Petersen RC, Cashman NR, Hutton M, Shaw CE, Boylan KB, Boeve B, Graff-Radford NR, Wszolek ZK, Caselli RJ, Dickson DW, Mackenzie IR, Petrucelli L, Rademakers R. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. <span><span class="ref-journal">PLoS Genet. </span>2008;<span class="ref-vol">4</span>:e1000193.</span> [<a href="/pmc/articles/PMC2527686/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2527686</span></a>] [<a href="/pubmed/18802454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18802454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.sreedharan.2008.1668">Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. <span><span class="ref-journal">Science. </span>2008;<span class="ref-vol">319</span>:1668–72.</span> [<a href="/pubmed/18309045" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18309045</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.steinacker.2008.1481">Steinacker P, Hendrich C, Sperfeld AD, Jesse S, von Arnim CA, Lehnert S, Pabst A, Uttner I, Tumani H, Lee VM, Trojanowski JQ, Kretzschmar HA, Ludolph A, Neumann M, Otto M. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. <span><span class="ref-journal">Arch Neurol. </span>2008;<span class="ref-vol">65</span>:1481–7.</span> [<a href="/pmc/articles/PMC2690860/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2690860</span></a>] [<a href="/pubmed/19001167" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19001167</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.synofzik.2014.1212.e1">Synofzik M, Born C, Rominger A, Lummel N, Sch&#x000f6;ls L, Biskup S, Sch&#x000fc;le C, Grasshoff U, Klopstock T, Adamczyk C. Targeted high-throughput sequencing identifies a TARDBP mutation as a cause of early-onset FTD without motor neuron disease. <span><span class="ref-journal">Neurobiol Aging. </span>2014;<span class="ref-vol">35</span>:1212.e1–5.</span> [<a href="/pubmed/24300238" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24300238</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.traynor.2000.109">Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. <span><span class="ref-journal">Arch Neurol. </span>2000;<span class="ref-vol">57</span>:109–13.</span> [<a href="/pubmed/10634456" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10634456</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.udan.2011.1">Udan M, Baloh RH. Implications of the prion-related Q/N domains in TDP-43 and FUS. <span><span class="ref-journal">Prion. </span>2011;<span class="ref-vol">5</span>:1–5.</span> [<a href="/pmc/articles/PMC3037998/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3037998</span></a>] [<a href="/pubmed/21135580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21135580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.uryu.2008.555">Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, Miller BL, Kretzschmar HA, Lee VM, Trojanowski JQ, Neumann M. Concomitant TAR-DNA-binding protein 43 is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2008;<span class="ref-vol">67</span>:555–64.</span> [<a href="/pmc/articles/PMC3659339/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3659339</span></a>] [<a href="/pubmed/18520774" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18520774</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.van_deerlin.2008.409">Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M, Steinbart E, McCluskey L, Grossman M, Neumann M, Wu IL, Yang WS, Kalb R, Galasko DR, Montine TJ, Trojanowski JQ, Lee VM, Schellenberg GD, Yu CE. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. <span><span class="ref-journal">Lancet Neurol. </span>2008;<span class="ref-vol">7</span>:409–16.</span> [<a href="/pmc/articles/PMC3546119/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3546119</span></a>] [<a href="/pubmed/18396105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18396105</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.van_blitterswijk.2012.3776">van Blitterswijk M, van Es MA, Hennekam EA, Dooijes D, van Rheenen W, Medic J, Bourque PR, Schelhaas HJ, van der Kooi AJ, de Visser M, de Bakker PI, Veldink JH, van den Berg LH. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. <span><span class="ref-journal">Hum Mol Genet. </span>2012;<span class="ref-vol">21</span>:3776–84.</span> [<a href="/pubmed/22645277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22645277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.weihl.2008.1186">Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, Hanson PI, Kimonis V, Pestronk A. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2008;<span class="ref-vol">79</span>:1186–9.</span> [<a href="/pmc/articles/PMC2586594/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2586594</span></a>] [<a href="/pubmed/18796596" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18796596</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.winton.2008.2252">Winton MJ, Van Deerlin VM, Kwong LK, Yuan W, Wood EM, Yu CE, Schellenberg GD, Rademakers R, Caselli R, Karydas A, Trojanowski JQ, Miller BL, Lee VM. A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. <span><span class="ref-journal">FEBS Lett. </span>2008;<span class="ref-vol">582</span>:2252–6.</span> [<a href="/pmc/articles/PMC2478749/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2478749</span></a>] [<a href="/pubmed/18505686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18505686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tardbp-als.REF.yokoseki.2008.538">Yokoseki A, Shiga A, Tan CF, Tagawa A, Kaneko H, Koyama A, Eguchi H, Tsujino A, Ikeuchi T, Kakita A, Okamoto K, Nishizawa M, Takahashi H, Onodera O. TDP-43 mutation in familial amyotrophic lateral sclerosis. <span><span class="ref-journal">Ann Neurol. </span>2008;<span class="ref-vol">63</span>:538–42.</span> [<a href="/pubmed/18438952" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18438952</span></a>]</div></li></ul></div></div><div id="tardbp-als.Chapter_Notes"><h2 id="_tardbp-als_Chapter_Notes_">Chapter Notes</h2><div id="tardbp-als.Author_Notes"><h3>Author Notes</h3><p><a href="http://www.cedars-sinai.edu/Research/Research-Labs/Baloh-Lab/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Baloh Laboratory</a></p><p><a href="http://millerlaboratory.wustl.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Miller Laboratory</a></p><p><a href="http://neuromuscular.wustl.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Neuromuscular Disease Center</a></p></div><div id="tardbp-als.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 March 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 May 2009 (cd) Revision: prenatal testing available</div></li><li class="half_rhythm"><div>23 April 2009 (et) Review posted live</div></li><li class="half_rhythm"><div>14 November 2008 (rhb) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK5942</span><span class="label">PMID: <a href="/pubmed/20301761" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301761</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/tango2-mea/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/tbc1d24-dis/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK5942&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK5942/?report=reader">PubReader</a></li><li><a href="/books/NBK5942/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK5942" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK5942" style="display:none" title="Cite this Page"><div class="bk_tt">Harms MM, Miller TM, Baloh RH. TARDBP-Related Amyotrophic Lateral Sclerosis. 2009 Apr 23 [Updated 2015 Mar 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK5942/pdf/Bookshelf_NBK5942.pdf">PDF version of this page</a> (467K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#tardbp-als.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#tardbp-als.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#tardbp-als.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#tardbp-als.Genetically_Related_Allelic_D" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#tardbp-als.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#tardbp-als.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#tardbp-als.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#tardbp-als.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#tardbp-als.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#tardbp-als.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#tardbp-als.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=23435[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TARDBP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK5942+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1487740" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1487740" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1487740" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1487740" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26131548" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CHCHD10</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CHCHD10</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ait-El-Mkadem S, Chaussenot A, Bannwarth S, Rouzier C, Paquis-Flucklinger V. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25577942" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">C9orf72</i>-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">C9orf72</i>-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cruts M, Engelborghs S, van der Zee J, Van Broeckhoven C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19192301" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Amyotrophic lateral sclerosis.</a><span class="source">[Orphanet J Rare Dis. 2009]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Amyotrophic lateral sclerosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wijesekera LC, Leigh PN. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2009 Feb 3; 4:3. Epub 2009 Feb 3.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29621978" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">High frequency of the TARDBP p.M337 V mutation among south-eastern Chinese patients with familial amyotrophic lateral sclerosis.</a><span class="source">[BMC Neurol. 2018]</span><div class="brieflinkpop offscreen_noflow">High frequency of the TARDBP p.M337 V mutation among south-eastern Chinese patients with familial amyotrophic lateral sclerosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Xu GR, Hu W, Zhan LL, Wang C, Xu LQ, Lin MT, Chen WJ, Wang N, Zhang QJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BMC Neurol. 2018 Apr 5; 18(1):35. Epub 2018 Apr 5.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301761" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301761" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc901175f66d18aa6ff592">TARDBP-Related Amyotrophic Lateral Sclerosis - GeneReviews®</a><div class="ralinkpop offscreen_noflow">TARDBP-Related Amyotrophic Lateral Sclerosis - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:10:42-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8BF993DFC8FD4100000000001F000D&amp;ncbi_session=CE8BF993DFC90111_0031SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK5942%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK5942&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK5942/&amp;ncbi_pagename=TARDBP-Related Amyotrophic Lateral Sclerosis - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8BF993DFC90111_0031SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>